Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results, presenting a buying opportunity due to raised 2025 revenue guidance. The company, a leader in ...

Tempus AI, a health tech firm, offers AI-powered platforms for treatment decisions, patient care, diagnostics, and molecular profiling, with growing revenue and improving margins. The "AI in ...

ctDNA profiling was performed using the Tempus xF assay that can detect variants in 105 genes in the ctDNA fraction. When the researchers analysed NCCN indication-matched variants that were ...

Skyrocketing 108% since the start of 2025, Tempus AI (NASDAQ: TEM), a company applying AI solutions to healthcare, has seen its stock perform exceptionally well this year. Investors have found the ...

Tempus AI stock faces mixed signals ahead of Q4 earnings, with short-term bearish pressure but technical support. Analysts see a 13.5% downside for Tempus AI, while technical indicators suggest ...